Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Amortization of Deferred Charges: 2020-2025

Historic Amortization of Deferred Charges for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to -$2.2 million.

  • Kymera Therapeutics' Amortization of Deferred Charges rose 39.61% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.1 million, marking a year-over-year increase of 15.72%. This contributed to the annual value of -$14.0 million for FY2024, which is 167.41% down from last year.
  • Per Kymera Therapeutics' latest filing, its Amortization of Deferred Charges stood at -$2.2 million for Q3 2025, which was down 3.16% from -$2.1 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Amortization of Deferred Charges ranged from a high of $1.7 million in Q3 2021 and a low of -$4.0 million during Q2 2024.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was -$2.2 million (2025), whereas its average is -$2.4 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Amortization of Deferred Charges plummeted by 1,998.28% in 2023, and later surged by 47.25% in 2025.
  • Over the past 5 years, Kymera Therapeutics' Amortization of Deferred Charges (Quarterly) stood at $1.6 million in 2021, then slumped by 155.32% to -$905,000 in 2022, then crashed by 40.22% to -$1.3 million in 2023, then tumbled by 157.45% to -$3.3 million in 2024, then surged by 39.61% to -$2.2 million in 2025.
  • Its Amortization of Deferred Charges stands at -$2.2 million for Q3 2025, versus -$2.1 million for Q2 2025 and -$2.5 million for Q1 2025.